生命科学资讯

Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate

Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program

Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech

Moderna's latest CMO steps down after barely a year

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront

AstraZeneca returns to China's CSPC for $18.5B obesity deal

Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact

Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine

Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor

AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B

The new rules of biopharma M&A: 4 trends driving dealmaking this year

Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says

New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill

Eikon sets $274M goal for upcoming stock market debut

Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M

Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss

Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report